2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 359

Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Abstract Number: 726

Tofacitinib Does Not Inhibit Dendritic Cell Maturation and T Cell Proliferation In Vitro
Abstract Number: 1471

Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: L9

Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
Abstract Number: 438

Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
Abstract Number: 2328

Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Abstract Number: 439

Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
Abstract Number: 802

Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Abstract Number: 441

Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
Abstract Number: 442

Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
Abstract Number: 1617

Toll-Like Receptor 3 Plays a Role In Loss Of Tolerance To The Ro/SSA Auto-Antigen In Systemic Lupus Erythematosus
Abstract Number: 2463

Tomosynthesis As a New Diagnostic Tool For Evaluation Of Ankylosing Spondylitis With Modified Stoke Ankylosing Spondylitis Spinal Score: A Comparison With Plain Radiographs
Abstract Number: 1809

Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Abstract Number: 661

Topoisomerase-1 Specific T Cells Exhibit a Proinflammatory Th17 Phenotype and Are Associated With Interstitial Lung Disease In Scleroderma
Abstract Number: 2121

Total Hip Arthroplasty Outcomes In Patients With Psoriatic Arthritis, Osteoarthritis With Cutaneous Psoriasis, and Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].